Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization
Reuters Released at: November 18, 2020 Upgraded at: November 18, 2020 18: 46 Pfizer Inc PFE.N said on Wednesday that last outcomes from the late-stage trial of its COVID-19 vaccine reveal it was 95% reliable, including it had the required two-months of safety information and would use for emergency situation U.S. permission within days. Pfizer […]
Released at: November 18, 2020
Upgraded at: November 18, 2020 18: 46
Pfizer said on Wednesday there had been 170 cases of the disease in its trial of more 43,000 volunteers, of which 162 were observed in the placebo arm and 8 were in the vaccine group.
” With hundreds of thousands of individuals around the world infected every day, we urgently require to get a safe and effective vaccine to the world,” Pfizer CEO Albert Bourla said in a statement.